Injectable Drug Market

Injectable Drug Market Overview for 2024 to 2034

The injectable drug market is evaluated to be sized at USD 5,97,980.6 million in 2024. During the period from 2024 to 2034, the market is expected to progress at a solid clip, registering a CAGR of 5.8%. By 2034, the injectable drug market is anticipated to have reached a value of USD 9,91,631.3 million.

Global Injectable Drug Market Overview

• Injectable drugs are associated with effective treatment of ailments as well as faster recovery times and thus preference for them is increasing among patients.
• Injectable drugs are considered practical in emergencies and as the capabilities of hospitals and medical workers to handle emergency situations increase, injectable drugs are seeing more application.
• Rise in the number of diabetes patients is leading to demand for insulin in injectable form to capitulate.
• Medical professionals recommending injections to their patients instead of oral medicine, for their effectiveness in getting rid of common problems like fever and cold, is influencing the market positively.
• Minimally invasive procedures are receiving the vote of confidence from a considerable number of patients and thus injectable drugs through injections are entering more bloodstreams.

Attributes	Details
Injectable Drug Market Value for 2024	USD 5,97,980.6 million
Projected Market Value for 2034	USD 9,91,631.3 million
Value-based CAGR of Market for 2024 to 2034	5.8%

Trends in the Prescription Delivery Services Market

• With the development of new infectious diseases putting the spotlight on vaccines, injectable drugs are increasingly being called upon to treat diseases permanently, or at least for the long term.
• Biotechnology is enabling the development of exciting new injectable drugs, for example, Etanercept (Enbrel) for rheumatoid arthritis, and these new medications are making sure the market remains fresh.
• Injection of new biologics drugs into the market like Imjudo (tremelimumab) and Elahere (mirvetuximab soravtansine) is keeping the demand for injectable drugs flowing.
• New drugs receiving approvals from regulatory bodies like the USA Food and Drug Administration (FDA) in increasing measure keeping the product line moving for market players.
• Sheer surge in the number of people getting affected by diseases like cancer and cardiovascular diseases is necessitating the administration of injectable drugs.
• Fear of needles among a considerable number of people, especially children, continues to be a rudimentary limiting factor for the market.
• Aversion to side effects of injectable drugs sees patients turn to other forms of treatment, constraining the growth of the market.

Category-wise Outlook

Monoclonal antibodies stand atop the pile in the product type segment. Intravenous (IV) injections remain the predominant mode of administration.

Rising Cancer Cases See Dependency on Monoclonal Antibodies Increase

Monoclonal antibodies are expected to account for 25.2% of the market share in 2024. Some of the factors influencing the increase in demand for monoclonal antibodies are:

• Alarming number of patients getting diagnosed with cancer is increasing the growing adoption of injectable monoclonal antibodies like Alemtuzumab and Bevacizumab.
• Various diseases like Crohn’s disease and ankylosing spondylitis come under the scanner of monoclonal antibodies. Injectable monoclonal antibodies like infliximab and adalimumab are thus seeing more frequent use.

Attributes	Details
Top Product Type	Monoclonal Antibody
Market Share (2024)	10.8%

Direct Approach of Intravenous (IV) Injections Preffered for Treatment

Intravenous (IV) injections are anticipated to account for 48.3% of the market share in 2024. Some of the reasons for the progress of intravenous (IV) injections are:

• Direct penetration of intravenous (IV) injections makes doctors and patients partial to them, with the direct route assuring greater absorption of the drug.
• Pain relief medications, antibodies, and more are all being delivered through the IV mode for the fast way the injection lets out the drug into the bloodstream. As demand for these types of drugs climbs, IV injections too are being administered more frequently.

Attributes	Details
Top Route of Administration	Intravenous (IV) injections
Market Share (2024)	48.3%

Country-Wise Analysis

Problems like the aging population and the rise in mental health problems are seeing the healthcare sector develop in Europe. The rise in patients is invariably leading to greater demand for injectable drugs.

The Europe Medicines Agency (EMA) approving injectable drugs for marketing and distribution at a fair rate is propelling the market in Europe. Governments in Europe striving to make healthcare affordable in Europe is also helping the market’s development.

Countries	CAGR (2024 to 2034)
Spain	4.0%
United Kingdom	3.0%
Italy	3.3%
France	3.4%
Germany	2.5%

Spanish Startups and Companies Attracting Foreign Investment

The CAGR of the market for the forecast period in Spain is anticipated to be 4.0%. Some of the factors influencing the growth of the market in the country are:

• Spanish startups and small-size players are advancing with the aid of foreign investment, or in some cases, like with the GES Group, getting taken over by foreign players.
• Injectable drugs for the treatment of schizophrenia are seeing greater adoption in Spain as cases of the ailment increase in the country.

Diabetes Treatment with the Help of Newly Developed Injectable Drugs Advancing in the United Kingdom

The market is expected to register a CAGR of 3.0% in the United Kingdom through 2034. Some of the factors responsible for the growth of the market are:

• Face of diabetes treatment is changing with the development of new injectable drugs. For example, it was announced in January 2024 that the Mounjaro device from Eli Lilly, with the injectable drug tirzepatide, would be made available in the United Kingdom for the treatment of type 2 diabetes.
• Cancer treatment is getting new facets in the United Kingdom with the help of injectable drugs. For example, in 2023, Atezolizumab was approved as a cancer treatment, with the effect of cutting treatment time as low as seven minutes.

Expansion of Medicine Producing Facilities Conducive to Growth of the Market in France

The market is expected to progress at a CAGR of 3.4% in France for the forecast period. Some factors influencing the progress are:

• France’s injectable drug-producing capabilities are developing fast. For example, CARBOGEN AMCIS opened a new facility for the production of sterile injectable drugs in France in 2023.
• Small-scale players and startups are teaming up with both local and foreign giants to increase their scope in the country.

Foreign Companies Expanding Footprint in Italy

The market is expected to progress at a CAGR of 3.3% in Italy throughout the forecast period. Some factors influencing the progress are:

• Foreign giants in the market are expanding their footprint in Italy. For example, in 2020, Thermo Fisher announced its intention to open a new sterile drug manufacturing facility in Monza, Italy.
• Infectious diseases proliferating is necessitating the use of injectable drugs in Italy.

Germany’s Aging Population Requiring Greater Number of Injectable Drugs

The market is expected to progress at a CAGR of 2.5% in Germany. Some factors influencing the progress are:

• With the population of Germany aging fast, injectable drugs are being administered in greater measure in the country.
• Market giants are making their way to Germany fast after sensing the market opportunities. For example, American company Eli Lilly and Co. announced plans to open its first production facility in Germany in November 2023.

Competitive Landscape in the Injectable Drug Market

The injectable drug market is moderately fragmented. Multinational companies are focusing on expanding production, while small-scale companies are looking for investments to remain competitive.

Pfizer Inc.’s personalized approach towards patients is seeing the company develop targeted injectable drugs. Other companies in the market are establishing partnerships between themselves to develop and advertise new products.

Recent Developments in the Injectable Drug Market

• In May 2023, French company MedinCell received approval from the FDA for its Uzedy (risperidone) injectable treatment.
• In August 2021, Cadila Healthcare partnered with Italian firm CHEMI SpA for the launch of its generic drug in the United States.
• In October 2020, EMA granted approvals for the marketing of two new injectable drugs called Rekambys (rilpivirine) and Vocabria injection (cabotegravir).

Key Companies in the Prescription Delivery Service Market

• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca Plc
• Merck & Co., Inc.
• Viatris + Mylan N.V
• Cipla Inc.
• Dr Reddy’s Laboratories Ltd.
• Samsung Biologics
• Abbott Laboratories
• Amgen Incorporated
• Baxter International Incorporated
• Becton Dickinson and Company
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Roche Holding Limited

Key Coverage in the Injectable Drug Market Report

• Injectable Drug Market Demand Analysis
• Injectable Drug Market Growth Assessment
• Global Injectable Drug Market Size and Share Report
• Sales Analysis Of Sterile Injectable Drugs
• Coverage of Opportunities For Injectable Drug Manufacturers
• Injectable Drug Market Share in Overall Medicine industry

Table of Content

• 1. Executive Summary
• 2. Market Overview
• 3. Market Background
• 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
• 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
  • 5.1. Monoclonal Antibodies
  • 5.2. Immunoglobulin
  • 5.3. Cytokines
  • 5.4. Insulin
  • 5.5. Peptide Hormones
  • 5.6. Blood Factors
  • 5.7. Peptide Antibiotics
  • 5.8. Vaccines
  • 5.9. Small Molecule Antibiotics
  • 5.10. Chemotherapy Agents
  • 5.11. Others
• 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
  • 6.1. Oncology
  • 6.2. Infectious Diseases
  • 6.3. Diabetes
  • 6.4. Blood disorders
  • 6.5. Hormonal Disorders
  • 6.6. Musculoskeletal Disorders
  • 6.7. CNS Diseases
  • 6.8. Pain Management
  • 6.9. Cardiovascular Diseases
• 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Molecule Type
  • 7.1. Small Molecules
  • 7.2. Large Molecules
• 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
  • 8.1. Intravenous (IV)
  • 8.2. Intramuscular (IM)
  • 8.3. Subcutaneous (SC)
• 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Drug Stores
  • 9.4. Online Pharmacies
• 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
  • 10.1. North America
  • 10.2. Latin America
  • 10.3. Western Europe
  • 10.4. Eastern Europe
  • 10.5. South Asia and Pacific
  • 10.6. East Asia
  • 10.7. Middle East and Africa
• 11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
• 18. Key Countries Market Analysis
• 19. Market Structure Analysis
• 20. Competition Analysis
  • 20.1. Pfizer Inc.
  • 20.2. Teva Pharmaceutical Industries Ltd.
  • 20.3. Sanofi S.A.
  • 20.4. Sun Pharmaceutical Industries Ltd.
  • 20.5. AstraZeneca Plc
  • 20.6. Merck & Co., Inc.
  • 20.7. Viatris + Mylan N.V
  • 20.8. Cipla Inc.
  • 20.9. Dr Reddy’s Laboratories Ltd.
  • 20.10. Samsung Biologics
  • 20.11. Abbott Laboratories
• 21. Assumptions & Acronyms Used
• 22. Research Methodology